Citation, commencement and extent

1.-(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 and comes into force on 31st May 2017.

(2) This Order extends to England and Wales and Scotland.

Amendment to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015

2.-(1) The Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015(2) is amended as follows.

(2) In paragraph 1(a) of Part 1 of the Schedule-

(a)before "Bufotenine" insert-

• "Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)

• N-Benzyl-ethylphenidate

• Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)";

(b)after "Cathinone" insert-

• "4'-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)";

(c)after "Concentrate of poppy-straw" insert-

• "Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

• 3,4-Dichloroethylphenidate

• 3,4-Dichloromethylphenidate (3,4-DCMP)

• Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Ethylnaphthidate

• Ethylphenidate";

(d)after "Eticyclidine" insert-

• "Etizolam";

(e)after "Etryptamine" insert-

• "Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

• 4-Fluoroethylphenidate

• 4-Fluoromethylphenidate

• Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)";

(f)after "Gamma-butyrolactone" insert-

• "3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Isopropylphenidate (IPP or IPPD)";

(g)after "Lysergide and other N-alkyl derivatives of lysergamide" insert-

• "Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)";

(h)after "Methcathinone" insert-

• "4-Methylmethylphenidate

• Methylmorphenate

• Methylnaphthidate (HDMP-28)

• Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]  diazepine)

• Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-  one)

• Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• Propylphenidate";

(i)after "Psilocin" insert-

• "Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)";

(j)after "3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)" insert-

• "3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)".

EXPLANATORY NOTE

(This note is not part of the Order)

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (S.I. 2015/704) by inserting a synthetic opioid (U-47,700), several methylphenidate related materials and a number of designer benzodiazepines into Part 1 of the Schedule to that Order.

An impact assessment will be published alongside the Explanatory Memorandum on the legislation.gov.uk website.